{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:34:02Z","timestamp":1782326042921,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.bbmt.2017.12.776","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T13:37:15Z","timestamp":1513172235000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-6160","authenticated-orcid":false,"given":"Avichai","family":"Shimoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose-Marie","family":"Hamladji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Delage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.12.776_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.beha.2011.05.002","article-title":"Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need","volume":"24","author":"Shimoni","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/bmt.2011.88","article-title":"Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike","volume":"47","author":"Danylesko","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0030","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics","volume":"19","author":"ten Brink","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","article-title":"Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients","volume":"62","author":"Munkelt","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0959-8049(02)00767-0","article-title":"Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)","volume":"39","author":"Fichtner","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0045","first-page":"5470","article-title":"Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients","volume":"60","author":"Westerhof","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exphem.2005.09.015","article-title":"Myeloablative and immunosuppressive properties of treosulfan in mice","volume":"34","author":"Sjoo","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0060","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","article-title":"Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning","volume":"28","author":"Casper","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","article-title":"Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)","volume":"37","author":"Kroger","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0070","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428190701671051","article-title":"Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"48","author":"Shimoni","year":"2007","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0075","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/bmt.2012.4","article-title":"Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity","volume":"47","author":"Shimoni","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0080","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bmt.2011.242","article-title":"Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning","volume":"47","author":"Casper","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0085","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","article-title":"Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0095","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ajh.24827","article-title":"Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning","volume":"92","author":"Shimoni","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0100","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0105","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2015.174","article-title":"Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies","volume":"50","author":"Yerushalmi","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.25764","article-title":"European Society for Blood and Marrow Transplantation analysis of treosulfan conditioning before hematopoietic stem cell transplantation in children and adolescents with hematological malignancies","volume":"63","author":"Boztug","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0115","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0125","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0130","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0140","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0145","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0150","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bmt.2014.133","article-title":"Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT","volume":"49","author":"Kharfan-Dabaja","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0155","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.leukres.2015.04.009","article-title":"Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"39","author":"Kharfan-Dabaja","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbmt.2016.11.023","article-title":"Survival advantage and comparable toxicity in reduced-toxicity treosulfan-based versus reduced-intensity busulfan-based conditioning regimen in myelodysplastic syndrome and acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation","volume":"23","author":"Sakellari","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0165","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3109\/08923973.2014.895743","article-title":"Cytostatic conditioning in experimental allogeneic bone marrow transplantation: busulfan causes less early gastrointestinal toxicity but treosulfan results in improved immune reconstitution","volume":"36","author":"Bouazzaoui","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.bbmt.2017.12.776_bib0175","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bbmt.2011.02.007","article-title":"Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life","volume":"17","author":"Alatrash","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117316804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117316804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:00:59Z","timestamp":1761058859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117316804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1083879117316804"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.776","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}